Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

References

• Aszalos A. (2007). Drug–drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects. Drug Discov Today 12:833–837.
   PubMed Web of Science ®Google Scholar
• Chan LM, Lowes S, Hirst BH. (2004). The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25–51.
   PubMed Web of Science ®Google Scholar
• Curtin NJ, Turner DP. (1999). Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro. Eur J Cancer 35:1020–1026.
   Google Scholar
• Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, Blunt JW, Munro MH, Gussio R, Hamel E. (2006). Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70:1866–1875.
   PubMed Web of Science ®Google Scholar
• Draft Guidance for Industry. 2006. Drug Interaction Studies—Study Design, Data Analysis, and Implications for Dosing and Labeling ( available at: http://www.fda.gov/cder/guidance/6695dft.pdf).
   Google Scholar
• Gramatté T, Oertel R. (1999). Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 66:239–245.
   PubMed Web of Science ®Google Scholar
• Greenberg ML, Fisher PG, Freeman C, Korones DN, Bernstein M, Friedman H, Blaney S, Hershon L, Zhou T, Chen Z, Kretschmar C. (2005). Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. Pediatr Blood Cancer 45:644–648.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L. (2005). The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086–1095.
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Olson ER, Pollack GM. (2007). Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. Drug Metab Dispos 35:455–459.
   Google Scholar
• Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH. (2002). Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943–2950.
   PubMed Web of Science ®Google Scholar
• Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA. (2004). Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64:5760–5766.
   PubMed Web of Science ®Google Scholar
• Lagas JS, Sparidans RW, van Waterschoot RA, Wagenaar E, Beijnen JH, Schinkel AH. (2008). P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin. Antimicrob Agents Chemother 52:1034–1039.
   Google Scholar
• Lin JH. (2007). Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 3:81–92.
   PubMed Web of Science ®Google Scholar
• Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P, Schinkel AH. (1996). Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 119:1038–1044.
   PubMed Web of Science ®Google Scholar
• Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP. (1998). Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to Taxol and doxorubicin. Clin Cancer Res 4:389–398.
   PubMed Web of Science ®Google Scholar
• Morris PG. (2010). Advances in therapy: eribulin improves survival for metastatic breast cancer. Anticancer Drugs 21:885–889.
   Google Scholar
• Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77:491–502.
   PubMed Web of Science ®Google Scholar
• Scripture CD, Figg WD. (2006). Drug interactions in cancer therapy. Nat Rev Cancer 6:546–558.
   PubMed Web of Science ®Google Scholar
• Seletsky BM, Wang Y, Hawkins LD, Palme MH, Habgood GJ, DiPietro LV, Towle MJ, Salvato KA, Wels BF, Aalfs KK, Kishi Y, Littlefield BA, Yu MJ. (2004). Structurally simplified macrolactone analogues of halichondrin B. Bioorg Med Chem Lett 14:5547–5550.
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S. (2004). Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 108:146–151.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031–2035.
   PubMed Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234.
   PubMed Web of Science ®Google Scholar
• Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, Ashworth S, Rosen LS. (2009). Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 15:4213–4219.
   PubMed Web of Science ®Google Scholar
• Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsk BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA. (2001). In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013–1021.
   PubMed Web of Science ®Google Scholar
• Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, Beare CM. (1997). Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 146:88–94.
   PubMed Web of Science ®Google Scholar
• Walle UK, Walle T. (1998). Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos 26:343–346.
   PubMed Web of Science ®Google Scholar
• Zhang ZY, King BM, Pelletier RD, Wong YN. (2008a). Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol 62:707–716.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. (2008b). A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709–724.
   PubMed Web of Science ®Google Scholar
• Zheng W, Seletsky BM, Palme MH, Lydon PJ, Singer LA, Chase CE, Lemelin CA, Shen Y, Davis H, Tremblay L, Towle MJ, Salvato KA, Wels BF, Aalfs KK, Kishi Y, Littlefield BA, Yu MJ. (2004). Macrocyclic ketone analogues of halichondrin B. Bioorg Med Chem Lett 14:5551–5554.
   PubMed Web of Science ®Google Scholar